Cargando…

Global cancer control: responding to the growing burden, rising costs and inequalities in access

The cancer burden is rising globally, exerting significant strain on populations and health systems at all income levels. In May 2017, world governments made a commitment to further invest in cancer control as a public health priority, passing the World Health Assembly Resolution 70.12 on cancer pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prager, Gerald W, Braga, Sofia, Bystricky, Branislav, Qvortrup, Camilla, Criscitiello, Carmen, Esin, Ece, Sonke, Gabe S, Martínez, Guillem Argilés, Frenel, Jean-Sebastian, Karamouzis, Michalis, Strijbos, Michiel, Yazici, Ozan, Bossi, Paolo, Banerjee, Susana, Troiani, Teresa, Eniu, Alexandru, Ciardiello, Fortunato, Tabernero, Josep, Zielinski, Christoph C, Casali, Paolo G, Cardoso, Fatima, Douillard, Jean-Yves, Jezdic, Svetlana, McGregor, Keith, Bricalli, Gracemarie, Vyas, Malvika, Ilbawi, André
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812392/ https://www.ncbi.nlm.nih.gov/pubmed/29464109 http://dx.doi.org/10.1136/esmoopen-2017-000285

Ejemplares similares

Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?
por: Eniu, Alexandru, et al.
Publicado: (2019)

ESMO and WHO: 14 years of working in partnership on cancer control
por: Ullrich, Andreas, et al.
Publicado: (2016)

Back to the ‘essence’ of medical treatment in oncology: the 2015 WHO Model List of Essential Medicines
por: Eniu, Alexandru, et al.
Publicado: (2016)

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers
por: Tabernero, Josep, et al.
Publicado: (2017)

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)
por: Morgan, Gilberto, et al.
Publicado: (2016)

Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty
por: Lordick, Florian, et al.
Publicado: (2019)

Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer
por: Prager, Gerald, et al.
Publicado: (2017)

ESMO Leaders Generation Programme: an alumni insight
por: Arruda, Leticia De Mattos, et al.
Publicado: (2018)

The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey
por: Saloustros, Emmanouil, et al.
Publicado: (2017)

Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells
por: Russo, Rosita, et al.
Publicado: (2019)

Applying the ESMO-Magnitude of Clinical Benefit Scale in real life
por: Ciardiello, Fortunato, et al.
Publicado: (2016)

Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016
por: van Krieken, Han, et al.
Publicado: (2016)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer
por: Martini, Giulia, et al.
Publicado: (2020)

Towards the era of precision medicine in metastatic colorectal cancer
por: Napolitano, Stefania, et al.
Publicado: (2020)

A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells
por: Landi, Nicola, et al.
Publicado: (2023)

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
por: Macarulla, T, et al.
Publicado: (2015)

Current models, challenges and best practices for work conducted between European academic cooperative groups and industry
por: Stahel, Rolf A, et al.
Publicado: (2020)

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care
por: Martinelli, Erika, et al.
Publicado: (2007)

Prioritising systemic cancer therapies applying ESMO’s tools and other resources to assist in improving cancer care globally: the Kazakh experience
por: Latino, N.J., et al.
Publicado: (2022)

Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients
por: Troiani, Teresa, et al.
Publicado: (2020)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941
por: Ciardiello, Davide, et al.
Publicado: (2022)

ESMO Copenhagen 2016: a lung cancer ‘grand cru’
por: Douillard, Jean-Yves
Publicado: (2017)

Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass
por: Orditura, Michele, et al.
Publicado: (2007)

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
por: Martinelli, Erika, et al.
Publicado: (2018)

Maximising clinical benefit with adequate patient management beyond the second line in mCRC
por: Argiles, Guillem, et al.
Publicado: (2019)

Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial
por: Siena, Salvatore, et al.
Publicado: (2016)

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
por: Morgillo, Floriana, et al.
Publicado: (2011)

Current options and future possibilities for the systemic treatment of hepatocellular carcinoma
por: Raoul, Jean-Luc, et al.
Publicado: (2019)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
por: Napolitano, Stefania, et al.
Publicado: (2022)

Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR
por: Giunta, Emilio Francesco, et al.
Publicado: (2022)

Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
por: Diana, Anna, et al.
Publicado: (2020)

Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?
por: Steenbruggen, Tessa G, et al.
Publicado: (2015)

Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer
por: Caputo, Vincenza, et al.
Publicado: (2023)

Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data
por: Sardo, Emilia, et al.
Publicado: (2022)

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines
por: Vitiello, Pietro Paolo, et al.
Publicado: (2019)

Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation
por: Napolitano, Stefania, et al.
Publicado: (2017)

One-step regression and classification with cross-point resistive memory arrays
por: Sun, Zhong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k4nh6ofhmjhe0ip1qqki7702o7